The Bio-inspired Artificial Pancreas (BiAP)

Reference number 8028

Sectors: Healthcare

Industries: Medical Devices

Proposed use

Artificial pancreas technology with automated insulin delivery for blood glucose control in people with type I diabetes (TID).

Problem addressed

Technological progress in the field of diabetes management has enabled the development of the artificial pancreas, an automated insulin delivery system for blood glucose control. The artificial pancreas consists of a subcutaneous continuous glucose sensor and a subcutaneous infusion pump that delivers insulin at a rate determined by an algorithm. Existing artificial pancreas solutions remain unable to achieve optimal glucose after meals and exercise, hence there is a need for improved control algorithms and implementation strategies.

Technology overview

We have introduced the Bio-inspired Artificial Pancreas (BiAP), the first and only closed-loop insulin delivery system based on mathematical modelling of the pancreatic beta-cell physiology.

Due to pharmacological limitations of currently available insulin formulations, artificial pancreas systems require user intervention to administer an additional insulin dose at mealtimes. For this purpose, BiAP incorporates an adaptive meal-insulin bolus recommender that learns from user and controller behaviours in order to provide superior meal-insulin dosing.

The BiAP control algorithm is designed for embedded low-power solutions (such as the hardware within insulin pumps, CGMs or smartwatches), has successfully been deployed in a dedicated microchip-based solution and more recently been realised in a smartphone-based platform.

BiAP is designed following a modular approach and can be easily integrated with existing predictive low-glucose suspension systems, glucose alarm systems, carbohydrate recommenders, insulin pumps, and continuous glucose sensors. It has also been extensively evaluated clinically in participants with type 1 diabetes within the following trials:

  • Feasibility studies including fasting conditions (n=20), overnight and following a standard meal (breakfast) challenge (n=20)
  • 24-hour randomised controlled clinical trial including unannounced meals, and underestimated carbohydrate content (n=12)
  • 24-hour randomised controlled clinical trial including standard exercise with insulin-only closed-loop control and insulin and glucagon closed-loop control (n=6)
  • 3-month crossover randomised controlled clinical trial in ambulatory conditions (n=20) (trial on-hold).
A diagram of the Modular Diabetes Management System (MDMS)

Left: Modular Diabetes Management System (MDMS). Highlighted icons correspond to the BiAP system; Right: Smartphone-based implementation of BiAP communicating to a continuous glucose sensor and insulin pump.

Benefits

  • Inspired by biology
  • Adaptive meal insulin bolus calculator
  • Clinically evaluated
  • State-of-the-art glycaemic control
  • Low-power algorithm that can be implemented directly in hardware such as handheld devices

Intellectual property information

WO 2018042147 A1 – AUTOMATIC CLOSED-LOOP GLUCOSE CONTROL WITH AN ADAPTIVE MEAL BOLUS CALCULATOR

 

Inventors

Professor Pantelis Georgiou

Professor of Biomedical Electronics
Faculty of Engineering, Department of Electrical and Electronic Engineering

Visit personal site
Portrait of Professor Nick Oliver
Professor Nick Oliver

Wynn Chair in Human Metabolism (Clinical)
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Visit personal site
Portrait of Dr Monika Reddy
Dr Monika Reddy

Consultant in diabetes and endocrinology
Faculty of Medicine

Visit personal site

Contact

Dr Marika Reay

Industry Partnerships and Commercialisation Senior Executive, Engineering

Dr Marika Reay is Industry Partnerships and Commercialisation Senior Executive for the Faculty of Engineering at Imperial College London

Contact Marika

+44 (0)20 7594 6867

m.reay@imperial.ac.uk

Related technologies

Acoustic sub-aperture processing (ASAP) for ultrasound vascular imaging

Acoustic sub-aperture processing (ASAP) for ultrasound vascular imaging

Ultrasound is one of the most commonly used clinical imaging modalities, characterized by its real-time capability, excellent safety, ... Find out more

ArterioWave – simple ultrasound-based diagnosis and monitoring of heart failure

ArterioWave – simple ultrasound-based diagnosis and monitoring of heart failure

More than 26 million people worldwide suffer from heart failure; there are around 1 million new cases annually in the US ... Find out more

Bioharmonophores for biomedical precision imaging

Bioharmonophores for biomedical precision imaging

Biodegradable, second-harmonic generating nanoprobes for targeted, high-resolution in vivo tumour imaging Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...